{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:05:37Z","timestamp":1790697937694,"version":"4.1.0"},"reference-count":16,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To assess visual outcomes and dosing frequencies of faricimab compared with other antivascular endothelial growth factor agents in treatment-na\u00efve and treatment-experienced eyes with diabetic macular edema.\n                    <jats:bold>Methods:<\/jats:bold>\n                    The de-identified electronic medical records of patients with diabetic macular edema in the Vestrum Health database between January 2021 and December 2023 were analyzed, including eyes treated with faricimab, bevacizumab, ranibizumab, and aflibercept. Through 6 injections for treatment-na\u00efve eyes and 2 injections for treatment-experienced eyes, we recorded changes in mean visual acuity (VA) and mean number of days between injections.\n                    <jats:bold>Results:<\/jats:bold>\n                    By injection 6, a total of 14\u2009103 treatment-na\u00efve eyes receiving faricimab (n = 167), bevacizumab (n = 7529), ranibizumab (n = 1433), and aflibercept (n = 4947) gained 4.6, 7.3, 7.1, and 6.7 letters, respectively. After stratifying by baseline VA, mean VA change in faricimab-treated eyes was statistically similar to that of eyes treated with other agents. After 2 injections, in 1378 eyes switched to faricimab from aflibercept, bevacizumab, and ranibizumab, mean letters gained were 0.8, 0.8, and 3.1, respectively. Eyes switched to faricimab improved similarly to those switched to aflibercept and ranibizumab, but had worse outcomes than eyes switched to bevacizumab (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .01). The percentage of treatment-na\u00efve eyes treated with faricimab that reached 50 or more mean days between injections 5 and 6 was significantly greater than eyes treated with bevacizumab and ranibizumab (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .01 for both).\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    VA outcomes for treatment-na\u00efve eyes receiving faricimab were similar to those of other eyes after adjustment for baseline VA. Furthermore, our findings suggest that faricimab may offer better durability outcomes than other antivascular endothelial growth factor agents.\n                  <\/jats:p>","DOI":"10.1177\/24741264261428771","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:04:21Z","timestamp":1775786661000},"page":"602-610","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Visual Acuity and Durability Outcomes of Faricimab Compared With Other Antivascular Endothelial Growth Factor Agents Within Routine Clinical Practice for Diabetic Macular Edema"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7226-1615","authenticated-orcid":false,"given":"Nathan N.","family":"Macha","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA"},{"name":"Retina Partners Midwest and Midwest Eye Institute, Carmel, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1225-154X","authenticated-orcid":false,"given":"Lucas W.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitika","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Vestrum Health, Naperville, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5859-8162","authenticated-orcid":false,"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Martin Health, Stuart, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-1846","authenticated-orcid":false,"given":"Raj K.","family":"Maturi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA"},{"name":"Retina Partners Midwest and Midwest Eye Institute, Carmel, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1909"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.2854"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2002"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells11121950"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2023.1192464"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6"},{"key":"e_1_3_3_8_2","volume-title":"Paper presented at: EURETINA Annual Meeting; Amsterdam","author":"Nielsen J","year":"2023","unstructured":"Nielsen J, Kahn H, Aziz A, et al. Real world efficacy, durability and safety of faricimab in diabetic macular edema: the TAHOE Study. Paper presented at: EURETINA Annual Meeting; Amsterdam; 2023."},{"key":"e_1_3_3_9_2","volume-title":"Paper presented at: American Society of Retinal Specialists Annual Meeting; Seattle","author":"Borkar D","year":"2023","unstructured":"Borkar D, Tabano D, Garmo V, et al. Early treatment patterns and outcomes in patients with diabetic macular edema treated with faricimab: the FARETINA-DME study. Paper presented at: American Society of Retinal Specialists Annual Meeting; Seattle; 2023."},{"key":"e_1_3_3_10_2","volume-title":"Paper presented at: EURETINA Annual Meeting; Amsterdam","author":"Bailey C","year":"2023","unstructured":"Bailey C, Tabano D, Borkar D, et al. FARETINA-DME- six-month treatment patterns and outcomes in patients with diabetic macular edema treated with faricimab: an IRIS registry analysis. Paper presented at: EURETINA Annual Meeting; Amsterdam; 2023."},{"key":"e_1_3_3_11_2","volume-title":"Paper presented at: EURETINA Annual Meeting; Amsterdam","author":"Bailey C","year":"2023","unstructured":"Bailey C, Peto T, Downey L, et al. FARWIDE-DME: early treatment patterns of faricimab among DME patients in the UK. Paper presented at: EURETINA Annual Meeting; Amsterdam; 2023."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181d87e04"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/24741264231221607"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.03.010"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.05.017"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-315933"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.4820"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261428771","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264261428771","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261428771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:26:08Z","timestamp":1790695568000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264261428771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/24741264261428771"],"URL":"https:\/\/doi.org\/10.1177\/24741264261428771","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]}}}